A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)

Trial Profile

A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Infliximab (Primary) ; Methylprednisolone (Primary) ; Prednisone (Primary)
  • Indications Diarrhoea
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 25 Aug 2017 Planned End Date changed from 17 Sep 2019 to 31 Mar 2017.
    • 25 Aug 2017 Planned primary completion date changed from 16 Dec 2018 to 21 Mar 2017.
    • 25 Aug 2017 Planned initiation date changed from 1 Dec 2016 to 16 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top